With LEAP and the 5-year follow-up study, we can feel comfortable deciding to start patients early on levodopa to maximize quality of life via motor symptom control.
In this study, there were no differences in UPDRS scores, the prevalence of wearing off, or levodopa equivalent daily dose between th...
Comments
at Portland VA PADRECC I agree. This is a patient-centered decision, but ...
I agree. This is a patient-centered decision, but ...